Sputum microbiota in adults with CF associates with response to inhaled tobramycin.
Administration, Inhalation
Adult
Anti-Bacterial Agents
/ administration & dosage
Cystic Fibrosis
/ drug therapy
Female
Forced Expiratory Volume
Humans
Longitudinal Studies
Male
Microbiota
/ drug effects
Powders
Pseudomonas
/ drug effects
Solutions
Sputum
/ microbiology
Staphylococcus
/ drug effects
Tobramycin
/ administration & dosage
Treatment Outcome
Young Adult
bacterial infection
bronchiectasis
cystic fibrosis
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
10
2019
revised:
03
08
2020
accepted:
09
08
2020
pubmed:
4
11
2020
medline:
16
12
2020
entrez:
3
11
2020
Statut:
ppublish
Résumé
Inhaled tobramycin powder/solution (TIP/S) use has resulted in improved clinical outcomes in patients with cystic fibrosis (CF) with chronic We drew sputum samples from a prospectively collected biobank. Patients were included if they had one sputum sample in the 18 months before and after TIP/S. Bacterial 16S rRNA gene profiling was used to characterise the sputum microbiome. Forty-one patients met our inclusion criteria and 151 sputum samples were assessed. At baseline, median age was 30.4 years (IQR 24.2-35.2) and forced expiratory volume in 1 (FEV Our longitudinal study demonstrates that the sputum microbiome of patients with CF is relatively stable following inhaled tobramycin over many months. Intriguingly, our findings suggest that baseline microbiome may associate with patient response to TIP/S-suggesting the sputum microbiome could be used to personalise therapy.
Sections du résumé
BACKGROUND
Inhaled tobramycin powder/solution (TIP/S) use has resulted in improved clinical outcomes in patients with cystic fibrosis (CF) with chronic
METHODS
We drew sputum samples from a prospectively collected biobank. Patients were included if they had one sputum sample in the 18 months before and after TIP/S. Bacterial 16S rRNA gene profiling was used to characterise the sputum microbiome.
RESULTS
Forty-one patients met our inclusion criteria and 151 sputum samples were assessed. At baseline, median age was 30.4 years (IQR 24.2-35.2) and forced expiratory volume in 1 (FEV
CONCLUSIONS
Our longitudinal study demonstrates that the sputum microbiome of patients with CF is relatively stable following inhaled tobramycin over many months. Intriguingly, our findings suggest that baseline microbiome may associate with patient response to TIP/S-suggesting the sputum microbiome could be used to personalise therapy.
Identifiants
pubmed: 33139451
pii: thoraxjnl-2019-214191
doi: 10.1136/thoraxjnl-2019-214191
doi:
Substances chimiques
Anti-Bacterial Agents
0
Powders
0
Solutions
0
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1058-1064Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MDP, HR and MS have received research support from CF Canada, CIHR and Gilead.